WO 2005/058376 PCT/US2004/042768

## WHAT IS CLAIMED IS:

5

1. A complex of an amphiphilic copolymer with a bioactive agent, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of said copolymer

- 2. The complex according claim 1 forms micelles in aqueous media.
- A complex according to claim 1, wherein the amphiphilic copolymer is comprised of a hydrophilic polymer selected from the group consisting of: a
   polyalkylether, dextran, dextran, carboxymethyldextran, dextran sulfate, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid, polylysine, polyaspartic acid, HPMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.
  - 4. A complex according to claim 1, wherein the ampiphilic polymer is a block copolymer made of hydrophilic and hydrophobic polymers.
- A complex according to claim 4, wherein the hydrophilic polymer is polyoxyethylene glycol, polyoxypropylene glycol, polyoxyethylene/propylene glycol, dextran, carboxymethyldextran, dextran sulfates, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid, polylysine, polyaspartic acid, HPMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.
- 6. A complex according to claim 5, wherein the hydrophilic polymer is polyethylene glycol.
  - 7. A complex according to claim 6, wherein the polyethylene glycol has a molecular weight of about 1000-10000

WO 2005/058376 PCT/US2004/042768

8. A complex according to claim 1, comprising a hydrophobic polymer, wherein the hydrophobic polymer is selected form a poly(alpha-hydroxy acid), polydioxanone, a polycarbonate, a polyanhydride, a polyorthoester, and a hydrophobic derivative of a poly(alpha-amino acid).

5

- 9. A complex according to claim 8, wherein the hydrophobic polymer is polylactic acid.
- 10. A complex according to claim 1, wherein the bioavtive agent is selected
   from the group consisting of topotecan, doxorubicin, adriamycin, vincristine, cisplatin, and a combination thereof.
  - 11. A complex according to claim 1, wherein the bioactive agent is topotecan.
- 15 12. A method of treating a cancer comprising administering an effective amount of the complex according to claim 1 to a patient in need thereof.
  - 13. Amethod of treating osteo arthritis, rheumatoid arthritis, diabetic retinopathy, hemangiomas or psoriasis comprising administering an effective amount of the complex according to claim 1 to a patient in need thereof.
  - 14. A complex of an amphiphilic copolymer with a contrast agent, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of said copolymer.

25

20

- 15. A method of diagnostic imaging comprising administering an effective amount of the complex according to claim 14 to a patient in need thereof.
- 16. A process of making an amphiphilic copolymer having benzoyl sulfonic
  acid groups by reacting the amphiphilic copolymer with sulfobezoic anhydride either in the melt or in solution.